Tsoulfas G, Goulis I, Giakoustidis D, Akriviadis E, Agorastou P, Imvrios G, Papanikolaou V
Surgical Department of Transplantation, Aristotle University, Hippokratio General Hospital, Thessaloniki, Greece.
Hippokratia. 2009 Oct;13(4):211-5.
Cirrhosis due to chronic hepatitis C is the leading indication for liver transplantation in Europe, United States and Japan. Reinfection after liver transplantation is universal and chronic liver disease develops in at least 70% of patients at 3 years, with an accelerated course compared to the nontransplant setting. These facts underscore the need for a better understanding of hepatitis C infection and the various treatment modalities. This paper attempts a brief review of the scope of the disease, as well as the different treatment modalities, with special emphasis given to orthotopic liver transplantation.
在欧洲、美国和日本，慢性丙型肝炎所致肝硬化是肝移植的主要适应证。肝移植后再感染很普遍，至少70%的患者在3年内会发展为慢性肝病，与未进行移植的情况相比，病程进展加快。这些事实凸显了更好地了解丙型肝炎感染及各种治疗方式的必要性。本文试图简要综述该病的范围以及不同的治疗方式，特别强调原位肝移植。
